Department of Radiology, Istanbul Fatih Sultan Mehmet Training and Research Hospital, Turkey.
Adv Clin Exp Med. 2022 Oct;31(10):1111-1119. doi: 10.17219/acem/150829.
Microwave ablation (MWA) is a safe and effective procedure for the treatment of benign thyroid nodules. The MWA causes progressive nodule shrinkage as well as the improvement of the symptoms and cosmesis. Some basic techniques have been described to further increase the efficacy and safety of this procedure.
To evaluate the efficacy of artery-first MWA as an advanced technique in the treatment of benign thyroid nodules.
A total of 40 patients treated with MWA were enrolled in the study. Nineteen patients who underwent artery-first MWA were selected for the study group and 21 patients who underwent MWA alone were included in the control group. Nodular vascularization was assessed using a new Doppler technique (Superb Microvascular Imaging (SMI)) and characterized using a 3-point scale. All patients were evaluated in terms of volume, symptoms, cosmetic scores, and laboratory findings before the procedure as well as 3 months (early-term follow-up) and 6 months (intermediate-term follow-up) after the procedure.
Both groups were comparable with respect to the baseline volume (p = 0.135). Nevertheless, the nodular volume reduction rate was significantly different at 3-month follow-up (study group: 56.97 ±11.39%, control group: 47.07 ±7.93%; p = 0.003) and 6-month follow-up (study group: 78.38 ±8.91%, control group: 69.54 ±9.41%; p = 0.004). In both groups, cosmetic and symptom scores decreased progressively (p < 0.005) and there were no major complications. Thyroid hormones and antibodies were within normal limits before the procedure, and no significant change was observed during follow-up after the ablation.
The artery-first MWA technique can be used in the treatment of benign thyroid nodules as a method of increasing the effectiveness of MWA.
微波消融(MWA)是治疗良性甲状腺结节的一种安全有效的方法。MWA 可导致结节逐渐缩小,并改善症状和美容效果。已经描述了一些基本技术,以进一步提高该程序的疗效和安全性。
评估动脉优先 MWA 作为治疗良性甲状腺结节的先进技术的疗效。
共纳入 40 例接受 MWA 治疗的患者。选择 19 例接受动脉优先 MWA 的患者作为研究组,21 例接受单独 MWA 的患者作为对照组。使用新的多普勒技术(Superb Microvascular Imaging(SMI))评估结节血管化,并采用 3 分制进行特征描述。所有患者在治疗前、治疗后 3 个月(早期随访)和 6 个月(中期随访)分别评估体积、症状、美容评分和实验室检查结果。
两组患者的基线体积无统计学差异(p = 0.135)。然而,3 个月随访时结节体积缩小率差异有统计学意义(研究组:56.97 ±11.39%,对照组:47.07 ±7.93%;p = 0.003),6 个月随访时差异仍有统计学意义(研究组:78.38 ±8.91%,对照组:69.54 ±9.41%;p = 0.004)。两组患者的美容和症状评分均逐渐下降(p < 0.005),且无严重并发症发生。治疗前甲状腺激素和抗体均在正常范围内,消融后随访期间无明显变化。
动脉优先 MWA 技术可作为提高 MWA 疗效的方法,用于治疗良性甲状腺结节。